No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: An observational cohort study

Rheumatology (United Kingdom)

Volumn 53, Issue 4, 2014, Pages 757-763

  Weber schoendorfer, Corinna ^a   Hoeltzenbein, Maria ^a   Wacker, Evelin ^a   Meister, Reinhard ^b   Schaefer, Christof ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Cohort study; Human; Low dose methotrexate; Malformation; Paternal; Pregnancy outcome; Rheumatoid arthritis; Spontaneous abortion; Teratogen

Indexed keywords

ANTIVITAMIN K; ETRETIN; ISOTRETINOIN; METHOTREXATE; MYCOPHENOLIC ACID; THALIDOMIDE; VALPROIC ACID;

ADULT; ADVERSE OUTCOME; ARTICLE; BIRTH DEFECT; BIRTH WEIGHT; COHORT ANALYSIS; CONCEPTION; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; INFORMATION SERVICE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPONTANEOUS ABORTION; TERATOLOGY; THERAPY;

COHORT STUDY; HUMAN; LOW-DOSE METHOTREXATE; MALFORMATION; PATERNAL; PREGNANCY OUTCOME; RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; TERATOGEN;

ABORTION, SPONTANEOUS; ADULT; ANTIRHEUMATIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; CONGENITAL ABNORMALITIES; FATHERS; FEMALE; HUMANS; MALE; METHOTREXATE; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES;

EID: 84897863165     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket390     Document Type: Article

References (35)

1. Schirm E, Pedersen L, Tobi H et al. Drug use among fathers around time of conception: two register based surveys from Denmark and the Netherlands. Pharmacoepidemiol Drug Saf 2004;13:609-13.
2. Viktil KK, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy-a population-based cohort study. Pharmacoepidemiol Drug Saf 2009;18:737-42.
3. De Santis M, Cesari E, Cavaliere A et al. Paternal exposure and counselling: experience of a Teratology Information Service. Reprod Toxicol 2008;26:42-6.
4. Lee CY, Jin C, Mata AM et al. A pilot study of paternal drug exposure: the Motherisk experience. Reprod Toxicol 2010;29:353-60.
5. Chapa JB, Hibbard JU, Weber EM et al. Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol 2003;101:1104-7.
6. Buckley LM, Bullaboy CA, Leichtman L et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997;40:971-3.
7. Visser K, Katchamart W, Loza E et al. Multinational evidence- based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
8. Longhi A, Macchiagodena M, Vitali G et al. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol 2003;25:292-6.
9. Evenson DP, Arlin Z, Welt S et al. Male reproductive capacity may recover following drug treatment with the L-10 protocol for acute lymphocytic leukemia. Cancer 1984;53:30-6.
10. Lamboglia F, D'Inca R, Oliva L et al. Patient with severe Crohn's disease became a father while on methotrexate and infliximab therapy. Inflamm Bowel Dis 2009;15:648-9.
11. Perry WH. Methotrexate and teratogenesis. Arch Dermatol 1983;119:874-5.
12. Beghin D, Cournot MP, Vauzelle C et al. Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol 2011;38:628-32.
13. Schaefer C, Ornoy A, Clementi M et al. Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations. Reprod Toxicol 2008;26:36-41.
14. Merks JH, van Karnebeek CD, Caron HN et al. Phenotypic abnormalities: terminology and classification. Am J Med Genet A 2003;123A:211-30.
15. Rasmussen SA, Olney RS, Holmes LB et al. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2003;67:193-201.
16. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
17. McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods 2004;9:403-25.
18. Little RJA, Rubin DB. Statistical analysis with missing data. New York: Wiley, 1987.
19. Mitra R, Reiter JP. A comparison of two methods of estimating propensity scores after multiple imputation. Stat Methods Med Res 2012 (Epub ahead of print) DOI:10.1177/0962280212445945.
20. Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studies-analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol 2008;26:31-5.
21. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012;41:196-201.
22. Cordier S. Evidence for a role of paternal exposures in developmental toxicity. Basic Clin Pharmacol Toxicol 2008;102:176-81.
23. Wilcox AJ, Treloar AE, Sandler DP. Spontaneous abortion over time: comparing occurrence in two cohorts of women a generation apart. Am J Epidemiol 1981;114:548-53.
24. Goldhaber MK, Fireman BH. The fetal life table revisited: spontaneous abortion rates in three Kaiser Permanente cohorts. Epidemiology 1991;2:33-9.
25. Goldhaber MK, Fireman BH. Re: 'Estimates of the annual number of clinically recognized pregnancies in the United States, 1981-1991'. Am J Epidemiol 2000;152:287-9.
26. Rempen A. [The incidence of abortions of viable pregnancies in the first trimester]. Zentralbl Gynakol 1993;115:249-57.
27. Saraiya M, Berg CJ, Shulman H et al. Estimates of the annual number of clinically recognized pregnancies in the United States, 1981-1991. Am J Epidemiol 1999;149:1025-9.
28. Nybo Andersen AM, Wohlfahrt J, Christens P et al. Maternal age and fetal loss: population based register linkage study. BMJ 2000;320:1708-12.
29. Osborn JF, Cattaruzza MS, Spinelli A. Risk of spontaneous abortion in Italy, 1978-1995, and the effect of maternal age, gravidity, marital status, and education. Am J Epidemiol 2000;151:98-105.
30. Hoesli IM, Walter-Gobel I, Tercanli S et al. Spontaneous fetal loss rates in a non-selected population. Am J Med Genet 2001;100:106-9.
31. Klemmt L, Scialli AR. The transport of chemicals in semen. Birth Defects Res B Dev Reprod Toxicol 2005;74:119-31.
32. Teo SK, Harden JL, Burke AB et al. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos 2001;29:1355-7.
33. Prahalada S, Tarantal AF, Harris GS et al. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology 1997;55:119-31.
34. Ben-Chetrit E, Ben-Chetrit A, Berkun Y et al. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res 2010;62:143-8.
35. Jenkins KJ, Correa A, Feinstein JA et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007;115:2995-3014.